122 related articles for article (PubMed ID: 37459029)
1. Incidence of breakthrough infections after COVID-19 vaccination among the COVID-19 vaccine recipients at a Tertiary Care Hospital in Srinagar.
Fazili A; Ain SN; Shah RJ; Raja FN; Farhat D; Nazir I
Indian J Public Health; 2023; 67(2):305-308. PubMed ID: 37459029
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough covid 19 infections after 2 doses of covid 19 vaccination and comparing severity between hospitalized and non hospitalized in tertiary care hospital.
S M; Hr C
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443499
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Covid-19 vaccines (CovishieldTM and Covaxin ®) in healthcare workers in Mumbai, India: A retrospective cohort analysis.
Contractor A; Shivaprakash S; Tiwari A; Setia MS; Gianchandani T
PLoS One; 2022; 17(10):e0276759. PubMed ID: 36301977
[TBL] [Abstract][Full Text] [Related]
4. Covid-19 vaccination in autoimmune rheumatic diseases: A multi-center survey from southern India.
Mohanasundaram K; Santhanam S; Natarajan R; Murugesan H; Nambi T; Chilikuri B; Nallasivan S
Int J Rheum Dis; 2022 Sep; 25(9):1046-1052. PubMed ID: 35773944
[TBL] [Abstract][Full Text] [Related]
5. Surveillance on Adverse Events Following COVISHIELD (ChAdOx1 nCoV-19) vaccination in Goa, India: An Observational Study.
Jose D; Dhupdale N; Cacodcar JA; Kamat U
Curr Drug Saf; 2023; 18(4):516-527. PubMed ID: 35927820
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India.
Doke PP; Mhaske ST; Oka G; Kulkarni R; Muley V; Mishra AC; Arankalle VA
Front Public Health; 2022; 10():1040012. PubMed ID: 36711329
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.
Kaur U; Fatima Z; Maheshwari K; Sahni V; Dehade A; Kl A; Yadav AK; Kansal S; Jaisawal V; Chakrabarti SS
Drug Saf; 2023 Jun; 46(6):553-563. PubMed ID: 37133805
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
[TBL] [Abstract][Full Text] [Related]
9. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
[TBL] [Abstract][Full Text] [Related]
10. Incidence and severity of COVID-19 infection post-vaccination: a survey among Indian doctors.
Parameswaran A; Apsingi S; Eachempati KK; Dannana CS; Jagathkar G; Iyer M; Aribandi H
Infection; 2022 Aug; 50(4):889-895. PubMed ID: 35129788
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.
Behera P; Singh AK; Subba SH; Mc A; Sahu DP; Chandanshive PD; Pradhan SK; Parida SP; Mishra A; Patro BK; Batmanabane G
Hum Vaccin Immunother; 2022 Dec; 18(1):2034456. PubMed ID: 35321625
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 Infection After Vaccination Among Healthcare Workers at a Tertiary Level Health Care Center in Northern India: A Cross-Sectional Study.
Sharma N; Singh M; Aggarwal P; Bahurupi Y; Panda PK; Saxena G
Recent Adv Antiinfect Drug Discov; 2022; 17(3):223-231. PubMed ID: 36221872
[TBL] [Abstract][Full Text] [Related]
13. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
Arora G; Taneja J; Bhardwaj P; Goyal S; Naidu K; Yadav SK; Saluja D; Jetly S
J Med Virol; 2022 Jul; 94(7):3147-3154. PubMed ID: 35261064
[TBL] [Abstract][Full Text] [Related]
14. Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north India.
Kaur U; Bala S; Ojha B; Jaiswal S; Kansal S; Chakrabarti SS
J Med Virol; 2022 Jan; 94(1):407-412. PubMed ID: 34491572
[TBL] [Abstract][Full Text] [Related]
15. Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.
Singh UB; Rophina M; Chaudhry R; Senthivel V; Bala K; Bhoyar RC; Jolly B; Jamshed N; Imran M; Gupta R; Aggarwal P; Divakar MK; Sinha S; Arvinden VR; Bajaj A; Shamnath A; Jain A; ; Scaria V; Sivasubbu S; Guleria R
J Med Virol; 2022 Apr; 94(4):1696-1700. PubMed ID: 34786733
[TBL] [Abstract][Full Text] [Related]
16. Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines.
Vicini S; Bellini D; Iannarelli A; Rengo M; Pelle G; Ruggiero S; Fusco M; Ambrogi C; Carbone I
AJR Am J Roentgenol; 2022 Nov; 219(5):752-761. PubMed ID: 35642761
[No Abstract] [Full Text] [Related]
17. COVID-19 vaccines breakthrough infection and adverse reactions in medical students: a nationwide survey in Iran.
Allahgholipour A; Safavi-Naini SAA; Shekarriz Foomany Z; Eskandari A; Nazari Rostami H; Honarvar MJ; Mohammadi M; Khalili P; Ilaghi M; Afshar H; Amini Baghbadorani A; Moghimi HR; Chamani Goorabi A; Mehrparvar A; Safari M; Nakhli AS; Mahmoudabadi M; Seifadini A; Sheikhansari S; Khojastehfar S; Mahdavi P; Mohammadi M; Ashrafi Barzideh S; Akbarzadeh N; Delavarpour Moghadam SH; Tavakoli Pirzaman A; Barary M; Emamhadi M
Front Public Health; 2024; 12():1348015. PubMed ID: 38544731
[TBL] [Abstract][Full Text] [Related]
18. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
[TBL] [Abstract][Full Text] [Related]
19. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.
Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A
J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
